Having a baby can be an extremely stressful and worrisome time for any parent. However, parents of children with spinal muscular atrophy (SMA) commonly share similar experiences. Many of them face a distressing late diagnosis due to shortcomings in NHS care, leading to feelings of guilt.
Initially, these parents bring home seemingly healthy babies, only to notice concerning changes as time goes by. The once-active kicking legs become less energetic, breathing becomes more difficult, and feeding poses challenges.
Despite repeatedly voicing their worries to healthcare professionals, including doctors and nurses, parents are often reassured that their babies are fine. As the babies struggle to thrive, some end up readmitted to hospitals, with a few even requiring intensive care for common infections.
Alarmingly, in numerous cases, parents resort to self-diagnosing their children with SMA after researching symptoms online. It is often the panicked parents who inform medical staff of the diagnosis, prompting confirmation through a simple blood test, albeit after irreversible damage has occurred.
Parents receive confirmation that their babies carry a genetic defect in the SMN1 gene, responsible for producing a protein crucial for nerve cell health maintenance. Without this protein, motor neurons perish, leading to muscle degeneration.
Fortunately, there are now three life-changing treatments accessible through the NHS that either rectify the defective gene or provide the needed protein to prevent further muscle loss, ultimately saving the child’s life. Nevertheless, parents are left grappling with the thought that earlier intervention could have resulted in a more normal life for their child, rather than one marked by severe disability.
It is unjust that parents, after diligently raising concerns that were dismissed by an unaware NHS system, must bear the weight of these consequences. The failure to proactively screen newborns for SMA perpetuates this double injustice.
The SMA community, known for its strong support system, offers solace to parents navigating this challenging journey. Despite the uncertainties surrounding the longevity of treatments, these children, once treated, can lead fulfilling lives, attending school, forming friendships, and bringing joy to those around them.
As the first generation of SMA patients with access to these treatments, their futures remain uncertain. However, their existence signifies a potential shift towards higher survival rates among SMA-afflicted children, paving the way for a future where SMA screening at birth becomes a standard practice in the UK.
The tireless advocacy of SMA parents has brought attention to the need for widespread screening, highlighting the importance of preventing others from enduring the same struggles they have faced. The collective efforts of these parents are driving change within the healthcare system, aiming to avert similar injustices in the future.